| Bioactivity | Cefpodoxime (Cefpodoxime acid) is a potent antibiotic active against gram-positive and gram-negative bacteria. Cefpodoxime inhibits the majority of cells in microbial populations. Cefpodoxime can be used for acute otitis media, sinusitis and tosillopharyngitis research[1][2]. |
| Invitro | Cefpodoxime (Cefpodoxime acid) inhibits gram-negative anaerobic rods (Bacteroidaceae) with MIC values of 0.125-4 mg/L. Cefpodoxime inhibits Veillonella parvula with MIC values of 0.25-8 mg/L. Cefpodoxime inhibits Peptostreptococcus micros, Peptostreptococcus asaccharolyticus and Ruminococcus bromii with MIC values of S. pneumoniae and S. pyogenes. cfu[2]. |
| In Vivo | Cephalosporins (2.5-50 mg/kg; p.o.; every 8 hours; for 48 hours) have good curative effect in mice[3]. Animal Model: |
| Name | Cefpodoxime |
| CAS | 80210-62-4 |
| Formula | C15H17N5O6S2 |
| Molar Mass | 427.46 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Werner H, et, al. Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis. Infection. 1991 Sep-Oct;19(5):377-9. [2]. Valentini S, et, al. In-vitro evaluation of cefpodoxime. J Antimicrob Chemother. 1994 Mar;33(3):495-508. [3]. Pérez-Trallero E, et, al. Prediction of in-vivo efficacy by in-vitro early bactericidal activity with oral beta-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin. J Chemother. 2001 Apr;13(2):118-25. |